Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
Viruses, 2015 There has been a remarkable transformation in the treatment of chronic hepatitis C in recent years with the development of direct acting antiviral agents targeting virus encoded proteins important for viral replication including NS3/4A, NS5A and NS5B ...
Asma Ahmed, Daniel J. Felmlee
doaj +3 more sources
Different Sequential Renal Involvement in a Patient With HIV and Hepatitis C: From HIV- or Leishmaniasis-Related Collapsing Glomerulosclerosis to Direct-Acting Antivirals' Renal Amyloidosis. [PDF]
Case Rep Infect DisMartín Gómez MA +5 more
europepmc +3 more sources
Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study [PDF]
Clinical and Molecular Hepatology, 2017 Background/Aims Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons.
Kwang Il Seo +5 more
doaj +1 more source
Acta Scientiarum. Health Sciences, 2023 To report the sociodemographic and clinical profile of patients treated with direct-action antivirals (DAAs). Patients infected with hepatitis C virus in current treatment were followed up in a pharmaceutical office.
Karem Aline Pegoraro +3 more
doaj +1 more source
Direct-acting antivirals for chronic hepatitis C [PDF]
Cochrane Database of Systematic Reviews, 2016 Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response ...
Jakobsen, Janus C. +15 more
openaire +8 more sources
SHARED: An International Collaboration to Unravel Hepatitis C Resistance
Viruses, 2021 The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...]
Anita Y.M. Howe +12 more
doaj +1 more source
Hepatitis C virus resistance to the new direct-acting antivirals [PDF]
, 2016 Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella +2 more
core +1 more source
Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go
Pharmaceuticals, 2019 Zika virus (ZIKV) is a mosquito-borne flavivirus that spread throughout the American continent in 2015 causing considerable worldwide social and health alarm due to its association with ocular lesions and microcephaly in newborns, and Guillain−Barr&
Juan-Carlos Saiz
doaj +1 more source
The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents [PDF]
African Journal of Gastroenterology and Hepatology, 2018 Background and aim Experts have reported thrombocytopenia is linked to chronic liver disease in up to 70% of patients with advanced fibrosis and portal hypertension. The occurrence of thrombotic thrombocytopenic purpura (TTP) with HCV infection is a rare
Amr Hanafy, Waseem Seleem, Salem Mohamed
doaj +1 more source
Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]
, 2017 Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero +11 more
core +1 more source